Ironwood Pharmaceuticals (IRWD) Deferred Taxes (2021 - 2026)

Ironwood Pharmaceuticals has disclosed Deferred Taxes across 6 years of filings, most recently posting $19.2 million for Q1 2026.

• Deferred Taxes for Q1 2026 came in at $19.2 million, up 2765.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.3 million (down 5.39% YoY), and the FY2025 annual result was $40.8 million, down 40.08% from the prior year.
• Deferred Taxes came in at $19.2 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$1.7 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $41.1 million in Q4 2024 to a low of -$1.7 million in Q4 2025.
• The 5-year median for Deferred Taxes is $14.7 million (2022), against an average of $15.7 million.
• Across the five-year window, Deferred Taxes sank 104.25% in 2025 and surged 2765.07% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Deferred Taxes stood at $20.1 million in 2022, then surged by 55.6% to $31.3 million in 2023, then surged by 31.23% to $41.1 million in 2024, then slumped by 104.25% to -$1.7 million in 2025, then soared by 1199.43% to $19.2 million in 2026.
• The last three Deferred Taxes figures came in at $19.2 million (Q1 2026), -$1.7 million (Q4 2025), and $27.8 million (Q3 2025), per Business Quant data.